Tag: Immutep
Immutep: Receives FDA Fast Track designation for NSCLC treatment
Immutep Receives FDA Fast Track designation for NSCLC treatmentImmutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a...
Immutep: Shares positive data from phase 2b AIPAC trial
Immutep Shares positive data from phase 2b AIPAC trialImmutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase...
Immutep: Completes Phase II recruitment
Immutep Completes Phase II recruitmentImmutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer
The last patient has now...
Immutep: Receives $3.4 million R&D tax incentive
Immutep Receives $3.4 million R&D tax incentiveImmutep (IMM) is granted a $3.4 million research and development tax incentive from the French Government
The...
Immutep: Advances phase two efti study for COVID-19 patients
Immutep's (IMM) phase two Eftilagimod Alpha Treatment COVID (EAT COVID) study will soon advance to enrolment ahead of the randomised portion
Up to...
Immutep: Invests nearly $30M for ongoing clinical trials
Biotech company Immutep (IMM) has tapped institutional investors for a neat $29.6 million to fund its cancer and autoimmune diseases treatment trials
The...